tiprankstipranks
3 Best Stocks to Buy Now, 4/4/2024, According to Top Analysts 
Market News

3 Best Stocks to Buy Now, 4/4/2024, According to Top Analysts 

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well. 

Don't Miss Our Christmas Offers:

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio. 

Terns Pharmaceuticals (NASDAQ:TERN) – This is a clinical-stage biopharmaceutical company. Yesterday, Jefferies analyst Akash Tewari assigned a Buy rating on the stock with a price target of $22 per share. Interestingly, four out of the five Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 156%. 

Shift4 Payments (NYSE:FOUR) – This company offers secure payment processing solutions. Yesterday, Citi analyst Ashwin Shirvaikar reiterated a Buy rating on the stock with a price target of $92 per share. Interestingly, nine out of the 10 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 32%. 

Biomea Fusion (NASDAQ:BMEA) –  This is a biopharmaceutical company that develops covalent small molecules to treat patients suffering from genetically defined cancers and metabolic disorders. Yesterday, Oppenheimer analyst Hartaj Singh maintained a Buy rating on the stock with a price target of $70 per share. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 290%.

Who are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. 

See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page. 

Disclosure 

Related Articles
TipRanks Auto-Generated NewsdeskBiomea Fusion Advances Diabetes Treatment with Positive Study Results
TheFlyBiomea’s icovamenib meets HbA1c standards in T2D, says H.C. Wainwright
TheFlyBiomea Fusion price target lowered to $50 from $60 at Oppenheimer
Go Ad-Free with Our App